Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated substantial weight reduction in clinical trials, while digital health technologies have emerged as scalable tools to support behavioral change and treatment adherence.^1,2 However, real-world evidence evaluating the integration of pharmacotherapy with digitally supported multidisciplinary care in Asian settings remains limited.³ New findings from a Singapore-based study demonstrated that a hybrid obesity care program combining physician-directed GLP-1 RA treatment with app-based lifestyle coaching achieved sustained and clinically meaningful improvements in body weight and cardiometabolic health over 18 months.³

Obesity is a chronic, relapsing disease associated with increased risk of cardiometabolic diseases.³ Lifestyle modification remains the cornerstone of obesity management, yet long-term weight reduction is often difficult to sustain without structured support.^3,4 Despite hybrid care models combining digital health technologies with human-led medical care and coaching emerging as scalable and effective approaches, evidence from multidisciplinary real-world programs remains limited, particularly in Asian settings.³

In view of this, a real-world study was conducted to evaluate the effectiveness of a hybrid obesity care program combining physician-directed GLP-1 RA treatment with app-based lifestyle coaching.³ The study evaluated the NOVI Optimus Plus program, a structured medical weight-loss intervention comprising physician-led GLP-1 RA management, health coaching, and a dedicated mobile application for self-monitoring and communication with the care team.³ The program incorporated individualized goal setting, GLP-1 RA dose adjustments, digital tracking of dietary intake and physical activity, and adaptive lifestyle coaching informed by real-time health data.³

The analysis included 708 adults with overweight or obesity (mean age 42.1 years; 64.1% female; 45.5% East Asian) recruited from an ethnically diverse Singapore population.³ Participants have either obesity (body mass index [BMI] ≥27.5kg/m² for Asians; ≥30kg/m² for non-Asians) or overweight (BMI ≥23kg/m² for Asians; ≥25kg/m² for non-Asians), with at least one weight-related comorbidity.³ Longitudinal outcomes in body weight and cardiometabolic parameters were assessed using mixed-effects models adjusted for age, sex, nationality, ethnicity, and comorbidity burden.³

Participants achieved substantial and sustained weight reductions over 18 months.³ Adjusted analyses showed mean weight loss of 9.2% (95% CI: -10.4 to -7.8) at 6 months, 12.7% (95% CI: -14.0 to -11.3) at 12 months, and 14.7% (95% CI: -16.0 to -13.3) at 18 months.³ BMI decreased from 31.9kg/m² at baseline to 28.9kg/m², 27.8kg/m², and 27.1kg/m² at 6, 12, and 18 months, respectively.³ These results were comparable to pivotal GLP-1 RA trials, supporting combined pharmacotherapy and structured behavioral support in routine care.³

Meaning improvements were also observed in cardiometabolic parameters.³ Waist-to-hip ratio declined from 0.83 to 0.80, systolic blood pressure decreased from 108.4mmHg to 95.0mmHg, body fat percentage reduced from 38.6% to 28.4%, and HbA1c declined from 5.1% to 4.4% over 18 months.³ These findings indicate that weight reduction translates into broader metabolic benefits consistent with established links between obesity, insulin resistance, hypertension, and cardiovascular disease.³ However, changes in lipid profiles were not statistically significant.³

Overall, this real-world evidence demonstrated that integrating physician-directed GLP-1 RA therapy with digitally supported behavioral coaching can deliver sustained weight loss and meaningful cardiometabolic improvements in individuals with overweight or obesity.³ As GLP-1 RAs continue to expand in obesity management, embedding structured behavioral and digital support within pharmacological programs may be essential to maximize long-term clinical benefit and improve patient outcomes.³